Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 877,746 |
|
|||||
| News | (1) | ||||||
| Day High | 218.4599 | Low High |
|||||
| Day Low | 213.14 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Biogen Inc | BIIB | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -3.38 | -1.56% | 212.75 | 19:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 217.99 | 213.14 | 218.4599 | 213.51 | 216.13 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 25,354 | 877,746 | US$ 214.91 | US$ 188,633,452 | - | 189.44 - 319.76 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 18:59:06 | 1 | US$ 212.01 | USD |
Biogen (BIIB) Options Flow Summary
Biogen Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 31.04B | 145.36M | - | 9.84B | 1.16B | 7.99 | 26.73 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Biogen News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BIIB Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 201.21 | 218.86 | 198.11 | 211.15 | 1,538,842 | 11.54 | 5.74% |
| 1 Month | 207.24 | 218.86 | 189.44 | 202.06 | 1,329,572 | 5.51 | 2.66% |
| 3 Months | 239.89 | 244.95 | 189.44 | 214.41 | 1,326,047 | -27.14 | -11.31% |
| 6 Months | 239.60 | 268.74 | 189.44 | 228.63 | 1,194,135 | -26.85 | -11.21% |
| 1 Year | 309.20 | 319.76 | 189.44 | 251.39 | 1,102,015 | -96.45 | -31.19% |
| 3 Years | 267.87 | 468.2499 | 187.16 | 265.61 | 1,236,779 | -55.12 | -20.58% |
| 5 Years | 229.83 | 468.2499 | 187.16 | 269.63 | 1,384,026 | -17.08 | -7.43% |
Biogen Description
| Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021. |
